Vena caval filters for prevention of pulmonary embolism
Referencias
Additional references
Buller HR, Agnelli G, Hull HD, Hyers TM, Prins MH, Raskob GE. Antithrombotic therapy for venous thromboembolic disease: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126(3):401‐28.
Douketis JD, Kearon C, Bates S, Duku EK, Ginsberg JS. Risk of fatal pulmonary embolism in patients with treated venous thromboembolism. JAMA 1998;279(6):458‐62.
Gomes MPV, Kaplan KL, Deitcher SR. Patients with inferior vena cava filters should receive chronic thromboprophylaxis. The Medical Clinics of North America 2003;87:1189‐1203.
Greenfield LJ. Evolution of venousiInterruption for pulmonary thromboembolism. Archives of Surgery 1992;127(5):622‐26. [MEDLINE: 1575633]
Hann CL, Streiff MB. The role of vena caval filters in the management of venous thromboembolism. Blood Reviews 2005;19:179‐202.
Kinney TB. Update on Inferior Vena Caval Filters. Journal of vascular interventional radiology 2003;14:425‐40.
Kirilcuk NN, Herget EJ, Dicker RA, Spain DA, Hellinger JC, Brundage SI. Are temporary inferior vena caval filters really temporary?. American Journal of Surgery 2005;190:858‐63.
Norris CS, Greenfield LJ, Hermann JB. Free‐floating iliofemoral thrombus: a risk of pulmonary embolism. Archives of Surgery 1985;120:806‐8.
Radomski JS, Jarrell BE, Carabasi RA, Yang S‐L, Koolpe H. Risk of pulmonary embolus with inferior vena caval thrombosis. American Surgeon 1987;53:97‐101.
Yusuf S, Mehta SR, Chrolavicius S, Afzal R, Pogue J, Granger CB, et al. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. New England Journal of Medicine 2006;354(14):1464‐76. [MEDLINE: 16537663; ClinicalTrials.gov number, NCT00139815]
